ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
Zoom Zoom: racing CARs for multiple myeloma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges.Biomedicines · 2026Review
- Article
- Review
- Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.Clinical and translational science · 2022Article
- Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.Biomedicines · 2021Article
- Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.Cells · 2020Review
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.Leukemia · 2020Review
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.Frontiers in immunology · 2019Review
- BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.Annals of translational medicine · 2018Article
- CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.Cancers · 2018Article
- CARs and other T cell therapies for MM: The clinical experience.Best practice & research. Clinical haematology · 2018Review
- Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.Leukemia & lymphoma · 2018Review
- Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Drugs · 2018Review
- Cellular and vaccine immunotherapy for multiple myeloma.Hematology. American Society of Hematology. Education Program · 2016Review
- Myeloid-derived suppressor cells: The green light for myeloma immune escape.Blood reviews · 2016Review
- Allogeneic stem cell transplantation for multiple myeloma: is there a future?Bone marrow transplantation · 2016Review
- Promising therapies in multiple myeloma.Blood · 2015Article
- The development of potential antibody-based therapies for myeloma.Blood reviews · 2015Review
- Targeting B-cell maturation antigen in multiple myeloma.Immunotherapy · 2015Review
- Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric antigen receptors redirect T cells to surface antigens. Discovery and validation of appropriate target antigens expand the possible indications for chimeric-antigen receptor (CAR)-T cells. B-cell maturation antigen (BCMA) is expressed only on mature B cells and plasma cells and promotes their survival. BCMA is a promising target for CAR-T cells in multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.